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Type 1 diabetes is the direct result of an autoimmune attack on the pancreatic islet
cells.  The islets contain b cells, which are the only type of cell capable of supplying
insulin in the human body.  The destruction of these cells leaves the diabetic to rely on
exogenous insulin to maintain a normal blood sugar level.  Without insulin injections the
patient’s body will be unable to utilize glucose and will break down fat for energy.  The
metabolism of fat leads to the production of ketone bodies, which acidify the blood,
leading to ketoacidosis.  Ketoacidosis is an emergency condition that can lead to coma or
even death.
Insulin therapy allows the diabetic patient to deal with the symptoms of the
disease, but does nothing for the underlying condition.  In order to truly cure the disease,
the strategy is to replenish the b cells in the diabetic.  Islet neogenesis associated protein
(INGAP) has been shown to regenerate islet cells and reverse experimentally-induced
diabetes in animal models.  The INGAP pentadecapeptide is a 15 amino acid peptide
from INGAP with comparable activity to the full-length protein.  This 15-mer is
undergoing clinical trials for treating diabetes.
The overall goal of the project described in this work is to determine the structure
of the INGAP pentadecapeptide for use in structure-based drug design of non-peptide
mimics of the 15-mer.  The first set of experiments in the present work directly examined
the 15-mer in solution using NMR.  No stable structure of the small peptide was found.
The second set of experiments involved a homolog of INGAP, called INGAP-related
protein, or INGAPrP.  INGAPrP was recombinantly produced in E. coli and subsequently
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purified and refolded.  Refolding of INGAPrP was verified by a 1H-15N HSQC
experiment.  CD experiments supported the NMR study, indicating helical content in
INGAPrP.  The folded nature of the protein will allow for the total three-dimensional
structure of INGAPrP to be determined.  The protein structure will show the fold of the
15-mer within the full-length protein.  This information will be valuable for the ultimate
goal of producing structural mimics of the INGAP pentadecapeptide.  Non-peptide
mimics should have better oral bioavailability and longer half-lives in vivo.
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CHAPTER 1
ISLET REGENERATION: A POTENTIAL CURE FOR TYPE 1 DIABETES
1.1 Type 1 Diabetes
There are an estimated 200 million people living with diabetes, of which some 20
million live in the United States (Zimmet et al., 2001).  Insulin-dependent diabetes
mellitus, or type 1 diabetes, accounts for approximately 10% of all diabetes cases
worldwide, while type 2 diabetes accounts for the vast majority.  Type 1 diabetes (T1D)
is an autoimmune disease in which the insulin-producing cells are destroyed, leaving the
patient dependent on exogenous insulin (Mathis et al., 2001).  Type 2 diabetes is usually
associated with obesity and is the result of a loss in the patient’s sensitivity to their
natural insulin (Moller, 2001).  Although the prevalence of T1D is much lower than type
2, a cure is still highly sought after due to the chronic nature of the disease and the long-
term complications associated with it.
T1D is usually diagnosed at a young age and is therefore also referred to as
juvenile-onset diabetes.  The classic symptoms include frequent hunger, urination, and
thirst (The Merck Manual, 1997).  Frequent hunger is the result of the body being unable
to utilize glucose as a source of energy since the absence of insulin renders the cells
unable to take-up glucose.  These excess sugar molecules then act as an osmotic diuretic,
which in turn leads to the increased thirst.  T1D is commonly diagnosed by two tests.
One test involves measuring a patient’s fasting blood glucose levels, while glucose levels
in the second test are measured after an oral glucose challenge.  Diabetics will register
high blood glucose levels on both tests.
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The main characteristic of T1D is the elevated blood sugar levels.  This
hyperglycemic state results from the extremely low levels of circulating insulin in the
diabetic.  Insulin is one of the hormones produced in the endocrine portion of the
pancreas and is secreted by the b cells in response to an increase in blood sugar levels.
The glucose transporters, GLUT2, on b cells transport excess glucose into the cells,
which causes a signaling cascade leading to the secretion of insulin (Saltiel and Kahn,
2001).  Thus, GLUT2 acts as the glucose sensors for the human body.  Without
functioning b cells, the diabetic loses the ability to detect increased blood glucose levels
and can not produce insulin.
Insulin is a 51 residue polypeptide consisting of two chains, A and B, connected
via two disulfide bonds (Stryer, 1995).  It is produced as a preprohormone.  The signal
peptide is cleaved in the endoplasmic reticulum and the prohormone is then packaged
into secretory vesicles in the Golgi.  In the Golgi, the prohormone is folded into its native
state and locked into this structure by the formation of the two disulfide bonds.  Protease
cleavage removes the center portion of the polypeptide, known as C-peptide, which
leaves the amino-terminal B-peptide bonded to the carboxy-terminal A-peptide, yielding
the functional insulin molecule (Figure 1.1).
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Figure 1.1 Insulin is produced as a preprohormone.  Removal of the signal peptide
(purple) produces proinsulin.  Disulfide bond formation (green) and removal of the C-
chain produce mature, biologically active insulin.
Insulin is secreted into the blood and exerts its action upon binding the insulin
receptor that is found on muscle and fat tissues.  The insulin receptor is a tyrosine kinase
receptor and consists of two a subunits and two b subunits (Saltiel and Kahn, 2001).  The
alpha subunits are extracellular and are responsible for binding insulin, while the b
subunits are intracellular.  Once insulin has been bound, the b  subunits are
autophosphorylated to become active.  The activated receptor then phosphorylates other
intracellular proteins triggering a signaling cascade.  The end result of the cascade is the
fusion of glucose transporters, GLUT4, to the cellular surface.  GLUT4 allows cells to
















that glucose can not be taken up from the blood, rendering the hyperglycemic state as
well as cellular starvation.
Although the etiology of T1D is not fully understood it is clear that the disease is
a direct result of reduction in b cell mass.  b cells are one of the four types of cells found
in the endocrine tissue of the pancreas, which contains cell clusters known as the Islets of
Langerhans (Stryer, 1995).  The other cell types, alpha, delta, and gamma produce
glucagon, somatostatin, and pancreatic polypeptide, respectively.  The islet cells
constitute only 5% of the pancreas, yet are crucial for normal metabolism.
Destruction of b cells is believed to be caused by an autoimmune attack directed
specifically at these cells.  Researchers have shown a correlation between the human
leukocyte antigen (HLA) region on chromosome six, specifically HLA-DQ and HLA-
DR, and susceptibility to T1D (Lernmark, 1999; Moustakas et al., 2002).  However, the
presence of these genes is not sufficient to cause the disease.  It is believed that an
environmental factor, possibly an unidentified virus or a bacterial toxin, sets off the chain
of reactions ultimately resulting in b cell depletion (Akerblom et al., 2002).
The HLA-DQ and HLA-DR genes produce antigens, which are presented by the
major histocompatibility complex (MHC) on b cells.  The HLA region allows the
immune system to differentiate between “self” and “non-self”, and in this way can
produce an immune attack on cells displaying pathogenic, “non-self”, antigens.
However, in the case of autoimmune diseases, the immune system mistakes “self”
antigens as those of a pathogen and a subsequent immune response is initiated to destroy
the cells.  In the T1D patient, their immune system has attacked the b cells.
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The autoimmune response is associated with antibodies against antigens on the b
cells.  There are three main b cell autoantibodies, which are directed at islet cell antigen-
2, glutamic acid decarboxylase (GAD65), and insulin itself, which have been correlated
with T1D (Verge et al., 1998).  Some researchers feel that these antigens could be an
early sign of disease propensity and could be used for early treatment, or even prevention
(Lernmark, 1999).
T-lymphocyte mediated b cell death occurs via two pathways (Notkins, 2002).
CD8+ cytotoxic lymphocytes recognize antigens bound to MHC-I on the b cell surface
(Figure 1.2).  CD4+ helper lymphocytes recognize processed antigens bound to MHC-II
molecules on the surface of antigen presenting macrophages and dendritic cells, resulting
in a reaction that destroys nearby b cells (Figure 1.3).
Figure 1.2  CD8+ destruction of b cells occurs through the MHC I presentation of an






CD8+ b cell Apoptosis
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Figure 1.3 CD4+ destruction of b cells occurs after the T-cell receptor recognizes an
autoantigen on an antigen presenting cell.  The subsequent signaling cascade leads to b
cell death.
Upon b cell destruction, and the nearly complete loss of circulating insulin, the
diabetes sufferer must turn to exogenous insulin to regulate glucose metabolism.
Supplying the diabetic with insulin will allow glucose to be utilized for energy and
subsequent storage of energy for later use.  Without insulin injections, the diabetic’s cells















for energy results in the accumulation of ketone bodies in the blood, rendering the blood
acidic.  This state, known as diabetic ketoacidosis, is an emergency condition that can
result in coma, or even death (The Merck Manual, 1997).
Life-threatening diabetic ketoacidosis is not the only risk associated with T1D.
T1D also causes many complications later in life due to constantly elevated blood sugar
levels, which damage blood vessels and nerves (Schwartz and Bornfeldt, 2003).  The
build-up of complex sugar-based substances can lead to plaque build-up in blood vessels.
This atherosclerosis causes poor circulation through blood vessels, which can damage the
heart, brain, legs, eyes, kidneys, nerves, and skin.  Some of the long-term complications
associated with T1D are retinopathy, nephropathy, and neuropathy (Bailes, 2002).
Retinopathy is caused by damage to the blood vessels of the retina, resulting in decreased
vision, and sometimes blindness.  Nephropathy is the term given to a damaged kidney.
When the blood vessels in the kidney thicken, it can malfunction or even result in
complete failure, rendering the patient to go on dialysis.  The inadequate blood supply
can also lead to neuropathy, or nerve damage.  This nerve damage can render a patient’s
limbs weak and unable to detect simple sensations, sometimes leading to amputation.
The current protocol for a T1D sufferer is to lower the blood sugar level through
daily shots of insulin.  The patient must monitor his or her blood sugar levels before and
after meals and administer the insulin when appropriate (The Merck Manual, 1997).  This
is difficult for people to do and still live a normal life.  It is especially hard on children
afflicted with T1D, whose parents must constantly watch over them.  The shortcomings
of insulin therapy have brought researchers to explore new T1D therapeutics.
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1.2 Therapeutic Strategies for Type 1 Diabetes
The unattractiveness of daily insulin injections and skin pricks to check blood
sugar levels, as well as the imperfect results of blood sugar regulation via insulin
injections, brings one to the conclusion that it would behoove the medical community to
discover alternative approaches to treat T1D.  There are several strategies currently being
studied, including islet transplantation, gene therapy, insulin mimics, and islet cell
regeneration (Yamaoka, 2003).
Islet transplants are now greater than 80% effective thanks to the advent of the
Edmonton Protocol (Shapiro et al., 2000).  The Edmonton Protocol uses pancreatic
material from two cadaveric donors to transplant enough functioning b cells into the
portal vein of the liver (Shapiro et al., 2000).  This location is optimal for transplantation
because of its seclusion from autoantibodies directed against b  cell antigens.
Unfortunately, the procedure relies on a life-long regimen of immunosuppressive drugs.
These drugs leave the body with a compromised immune system that often leads to
opportunistic infections.  However, the main problem with this therapy is the severely
limited number of donor pancreases.  Only ~3000 organs become available in the United
States each year, and the technique requires islets from two donors for each transplant.
This is obviously not nearly enough for the two million type 1 diabetes sufferers.
Gene therapy strategies for T1D involve integration of the insulin gene under
control of a specific promoter, which will be activated upon increased glucose
concentration (Yoon, 2002; Fenjves, 2000).  Gene therapy has the advantage over other
approaches in that it will not fall victim to a repeat autoimmune attack.  This method has
shown promise in animal models, however, there are several barriers.  Regulation of the
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transgenic insulin production has been problematic, meaning that either too little or too
much insulin is produced (Kolodka, 1995; Tuch, 1998).  Not enough insulin means that
the diabetic will experience high blood sugar levels, and too much insulin can lead to a
potentially lethal state of hypoglycemia.  As with all gene therapy approaches, another
concern is how to deliver the gene to the desired location within the human genome.
These problems will have to be overcome before the gene therapy approach is a viable
T1D treatment option.
A specific example of using gene therapy as a strategy to reverse T1D was
accomplished by researchers at Emory University (Thule and Liu, 2000).  Their system
relied on hepatic production of insulin following gene transfer to hepatocytes.  Insulin
expression was controlled by glucose responsive elements from the pyruvate kinase gene,
thus acting as the glucose sensor.  This method was shown to be effective in maintaining
normal blood sugar levels following glucose challenges in STZ diabetic rats.  This study
offers hope for the gene therapy paradigm of T1D treatment.
Insulin mimics are another avenue being explored to treat T1D (Qureshi et al.,
2000; Ding et al., 2002).  An insulin mimic is a small molecule that will bind to and
activate the insulin receptor, thereby translocating GLUT4 to the cellular surface to
provide up-take of glucose into the cell.  Insulin mimics have the advantage over insulin
in that they would be orally available as opposed to insulin, which must be injected.
However, patients would still have to monitor blood sugar levels before and after meals
and take an insulin mimic accordingly.
Islet regeneration therapy holds a distinct advantage over gene therapy and insulin
mimics in that islet regeneration would treat the underlying cause of T1D, whereas the
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other two alternatives only treat the symptoms (Yamaoka, 2002).  Islet regeneration can
be done in vitro with subsequent transplantation of the islets, or it can be done in vivo.
Either way the patient is provided with a functioning mass of b cells to regulate blood
sugar levels.  The main drawback of islet regeneration is that subsequent destruction of
the newly produced b cells will likely occur via the same mechanism that originally
caused T1D.  Therefore, researchers must think in terms of a two-prong approach in
which new islets are introduced in a patient and the immune attack directed at the cells is
halted.
1.3 Regenerative Medicine
Regenerative medicine can be thought of as a way to repair or replace failing
human tissue or organs.  The general strategy involves harvesting pluripotent cells,
growing the cells in the lab, and stimulating the cells to form specific tissues (Heber-
Katz, 2004).  These tissues are then examined and shown to be effective before
placement into a diseased body.
Alternatively, pluripotent adult stem cells can be differentiated within the human
body (Rosenberg 1995).  This however would theoretically only provide temporary relief
of the disease because whatever caused the disease in the first place would happen again.
In this sense, in vivo regenerative medicine is at a disadvantage because with in vitro
regeneration researchers can modify the cells in such a way to prevent a reiteration of
disease progression.  In vivo regeneration is also difficult because the factors responsible
for differentiating pluripotent cells are often peptides or proteins that are prone to swift
degradation in the body.
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Although there are some hurdles yet to be cleared, regenerative medicine gives
hope to patients with a myriad of diseases.  The diseases hoped to be curable via
regenerative medicine include Parkinson’s disease, Alzheimer’s disease, arthritis,
osteoporosis, emphysema, liver cirrhosis, heart disease, cystic fibrosis, and diabetes
(Herber-Katz, 2004).
T1D is an attractive target for regenerative medicine because it involves
replacement of only one type of cell, namely the pancreatic b cell.  Replenishment of
insulin-producing b cells within a diabetic patient coupled with a therapy to prevent
destruction of the new b cells could reverse the disease state (Sumi and Tamura, 2000).
Thus, regenerative medicine offers real hope to T1D sufferers.
1.4 Islet Regeneration
Islets are known to have the ability to regenerate (Rosenberg, 1995; Wilkin,
1998).  Research conducted from 1902 to 1914 showed that islet and acinar regeneration
occurred after pancreatic duct obstruction (Shaw et al., 1926).  In 1924, these same cells
were observed to regenerate after near total pancreatectomy (Shaw et al., 1926).  In 1947,
Hughes found that pancreatic injury, resulting from administration of a b cell toxin,
alloxan, in rats caused an initial loss of islets but then noticed an increase in islet number
in a subsequent regenerative phase (Hughes, 1947).  This same phenomenon was
observed in the 1980s when streptozotocin, a b cell toxin, was administered to neonatal
rats (Cantenys et al., 1981).
There are two hypotheses for the mechanism of regeneration in vivo (Bouwens,
1998).  One idea is that new islets are spawned from residual stem cells.  A second
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hypothesis is that new islets are produced from proliferation of existing b cells (Dor et
al., 2004).  Both of these mechanisms may be viable pathways to produce insulin-
expressing cells.  Although the debate continues as to the mechanism of regeneration, one
thing is certain: finding the factors responsible for producing new islets could lead to a
cure for T1D.
The first protein isolated from regenerating pancreata was the Reg, or
regenerating, protein (Terazono et al., 1988).  Researchers produced an animal model of
diabetes in which a diabetic state was induced by 90% pancreatectomy.  The researchers
then began treatment with the poly(ADP-ribose) (PARP) synthetase inhibitor
nicotinamide.  Overproduction of PARP can lead to tissue necrosis, so the hypothesis was
that nicotinamide could stop cell death, leading to regeneration of the pancreatic tissue.
Exocrine and endocrine cell regeneration was noticed with the presence of the Reg
protein.  This regenerating factor was expressed only in regenerating pancreata and not in
normal animals.  The protein was shown to improve the diabetic state in an animal model
as evidenced by a significant decrease in blood glucose levels and an increase in b cell
mass (Watanabe et al., 1994).
Reg has also been seen in other models of islet regeneration.  A method to reverse
b cell damage was investigated by administration of an antioxidant, probucol, to STZ
diabetic hamsters (Takatori, 2003).  The hypothesis was that oxidative damage to islets
was key in the pathogenesis of diabetes.  The researchers found that upon administration
of probucol, Reg and islet neogenesis associated protein (INGAP) gene expression were
upregulated.  The study concluded that there was partial restoration of b cell function,
likely due to the increased presence of Reg and INGAP.
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Since the Reg protein was identified, many other factors have been discovered
which cause islet generation both in vivo and in vitro.  Some of these include glucagon-
like peptide-1 (GLP-1) (Hui et al., 2001; Buteau et al., 2003), exendin-4 (U.S.
Department of Health and Human Services, 2000), dipeptidyl protease IV inhibitors
(Probiodrug, 2002), islet neogenesis associated protein (Rafaeloff et al., 1997), rat
pancreatic extract (Soo Kim 2003), epidermal growth factor (EGF) (Brand et al., 2002),
gastrin (Brand et al., 2002), transforming growth factor-a (Sandgren et al., 1990),
betacellulin (Watada et al., 1996), activin (Mashima et al., 1999), insulin-like growth
factor-I (IGF-I) (George et al., 2002) and interferon-gamma (Gu 1993).  Several review
articles have been written that cover these regeneration factors (Yamaoka and Itakura
1999; Nielsen et al., 1999; Sumi and Tamura, 2000; Soria, 2001; Risbud and Bhonde,
2002; Yamaoka, 2002).  It should be pointed out that some of these factors may not have
to be administered to the patient but could be produced in vivo through use of gene
therapy to deliver the gene encoding the protein factor of interest, leading to subsequent
expression and islet regeneration (Yamaoka 2001),
Other factors of importance include transcription factors, such as the pancreatic
duodenal homeobox gene, PDX-1, also referred to as IDX-1 (Sumi and Tamura, 2000;
Gagliardino et al., 2003).  This gene is a requisite for islet generation from stem cells.  It
is believed to be active in the normal pancreatic development during the fetal stage.
Another transcription factor is neurogenin-3 (Ngn-3), which is also key in islet
differentiation (Vetere et al., 2003).  Researchers hope to exploit this knowledge by
identifying cells with these transcription factors as candidates for islet generation.  One
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can imagine developing cell lines with high levels of PDX-1 or Ngn-3 for mass
production of islet cells, or targeting PDX-1/Ngn-3 expressing cells in vivo.
As already mentioned, the paradigm of islet regeneration consists of two steps.
The first step is to generate insulin-expressing cells in vivo, or to generate the cells in the
lab and then transplant them into the patient (i.e. Edmonton Protocol).  This step has been
explored above.  The second step is to prevent these newly supplied cells from being
attacked by the immune system.  Researchers have come up with several ways to combat
the autoimmune response (Cotterell and Kenyon, 2002).
Encapsulation of islet cells produced in the lab prior to transplantation could
prevent immune destruction (Gray, 1997; Maria-Engler et al., 2001).  Cells can be
encapsulated by various polymers, which strategically allow influx of nutrients and
outflow of insulin, but prevent the up-take of antibodies directed at the islets.  The
polymeric thickness can be controlled so that encapsulated cells will have a wide range of
diffusion properties, potentially allowing for fine tuning of insulin release.
Another way to prevent immune attack of islet cells is to modify their cell
surfaces so that they will not display the aforementioned b cell autoantigens (Yamaoka,
2001).  Manipulating the cells’ properties prior to transplantation should be a
straightforward and powerful tool to reduce the chances of a recurrent immune attack.
A third method researchers hope to develop that will spare transplanted islets is
by targeting the immune system itself.  This is being investigated via monoclonal
antibody therapy (Keymeulen et al., 2005).  Monoclonal antibodies will bind to the
autoantibodies directed at the diabetic’s islet cells, thus destroying the autoantibodies’
function.
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With the advent of so many methods to produce islets in vivo and in vitro, and
new methods of protection from autoimmune response, it seems that it is only a matter of
time before T1D can be cured by islet regeneration therapy.  Figure 1.4 illustrates the
necessary steps to treat T1D via in vitro islet regeneration.
Figure 1.4 Summary of T1D treatment by islet regeneration.
Adult Islets --> Proliferate
Fetal Islets --> Proliferate/Differentiate
Cultured b cells
Cultured Pancreatic Ductal Cells --> Differentiate
Embryonic Stem Cells --> Differentiate
Animal Islets --> Destroy Viruses









2.1 INGAP: Discovery and Activity
The search for INGAP started in 1983, when researchers found that wrapping the
head of a hamster pancreas caused islet cell growth (Rosenberg et al., 1995).  The
experiment was intended to induce pancreatitis, but instead of inflammation the
researchers noticed new islet formation.  The researchers termed this the “partial duct
obstruction” model of islet regeneration (Rosenberg, 1998).
Rosenberg’s method of partial duct obstruction allowed for subsequent islet
formation to be studied without pancreatitis, autoimmune destruction, or tissue atrophy.
The islet cell neogenesis did not appear to be mitotic division of existing b cells, but
rather reiteration of normal ontogeny from ductular cell precursors.
Immunocytochemical techniques confirmed mature islets were produced that expressed
insulin, glucagon, and somatostatin (Rosenberg, 1998).
The ultimate test for Rosenberg’s model of islet regeneration was to evaluate the
cellophane wrapping technique to see if it could reverse a diabetic state.  Using hamsters
treated with streptozotocin (STZ), and therefore diabetic, the test was passed (Rosenberg,
1998).  New islets formed and the diabetic state was reversed in greater than 50% of the
animals.  These animals now had normal serum glucose and insulin levels.  The next step
was to determine what was causing this reversal.
Using standard fractionation and protein chemistry techniques, an extract, termed
Ilotropin, was identified in the regenerating pancreata that was not in normal pancreata
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(Pittenger et al., 1991).  Ilotropin was found to be protease sensitive, acid stable, heat
stable, alcohol precipitable, and had a molecular weight range of 29-44 kD.  It was
apparent this compound was a protein, however it appeared to be a mixture of several
proteins.
The researchers, led by Dr. Vinik and Dr. Rosenberg, turned to another strategy to
firmly establish which factor was causing this unexpected reaction.  They used a
technique called mRNA differential display (Liang and Pardee, 1992).  The technique
uses poly dT affinity chromatography to isolate mRNA from various cells or organs and
then allows the user to compare which mRNAs are present in the subsets of cells.  For
example, the technique can be used to look at which mRNAs are present in a lung cancer
cell but not present in a normal lung cell.  This gives researchers a method to elucidate
causes of a disease and to determine which proteins may be valid targets for therapeutic
intervention.
In the case of INGAP, researchers used mRNA differential display and identified
ten mRNA transcripts that were uniquely or over-expressed in the regenerating pancreata
but absent, or expressed at very low levels, in normal hamster pancreases (Rafaeloff et
al., 1996).  One clone in particular, RD 19-2, was found to be of extreme interest.  RD
19-2 had some homology to the Reg gene, which instantly made it a candidate to be the
cause of islet regeneration.  It was also found to be maximally expressed at 1-2 days
following cellophane wrapping of the pancreas without expression at any other time, and
was not observed in normal pancreata.  The researchers reasoned that the gene product
may be upregulated following the apparent pancreatic injury, which would lead to a
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regeneration of islet mass to compensate for the tissue trauma caused by the cellophane
wrapping.
RD 19-2 was later termed the INGAP gene (Rafaeloff et al., 1997).  The name is
an acronym for islet neogenesis associated protein.  The mRNA transcript is 766 bp and
the encoded INGAP protein is 175 amino acids long.  Tissue-specific expression was
determined via Northern blotting.  It was demonstrated that INGAP RNA was present in
pancreas and duodenum, but not observed in spleen, stomach, lung, liver, heart, or
muscle.  A Western blot using antibodies raised against INGAP demonstrated that
INGAP was a component of the earlier protein mixture, Ilotropin, identified by the
researchers.  Thus, the mRNA differential display proved successful.
The next test was to see if this protein could reverse experimental diabetes in an
animal model.  The researchers cloned the gene into an expression vector for recombinant
production in E. coli.  Figure 2.1 shows the amino acid sequence of INGAP.  It was
found that in order to express the protein, the researchers needed to exclude the signal
peptide, which is the first 26 amino acids.  Upon expression, the protein was purified by
use of the his-tag at the N-terminus (Vinik et al., 1998).  The protein was then dialyzed








Figure 2.1 INGAP sequence.  The first 26 residues constitute the signal peptide and are
shown in brown.  The INGAP pentadecapeptide is shown in blue.
In vitro testing was done with the ARIP cell line, which is isolated from rats and
is a ductal epithelial cell line.  Dr. Vinik’s team incubated ARIP cells with INGAP and
measured the [3H]-thymidine uptake from the media (Rafaeloff et al., 1997).  [3H]-
thymidine was indeed taken-up from the media, indicating that the cells were dividing.
This was an encouraging finding since proliferation of ductal cells is a prerequisite for
islet neogenesis.
STZ-induced diabetic mice and hamsters were chosen as animal models.  INGAP
was found to be active and could reverse STZ-induced diabetes in greater than 50% of
the test animals (Gold et al., 1998).  Quite an accomplishment, however, the researchers
knew that taking a relatively large protein like INGAP into clinical trials may be difficult
because it would be rapidly destroyed by proteolytic activity in vivo.  They strived for a
better compound to take into the clinic.  The INGAP sequence was searched, and the
researchers found a region that was promising for biological activity.
The stretch of amino acids from 104 to 118 (Figure 2.1) within INGAP had
potential biological activity for two reasons, according to the researchers (Rafaeloff et al.,
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1997).  This region of INGAP differs from Reg because of a unique insertion of five
amino acids, SHGTL.  It was apparently believed that this may make INGAP somehow
more active than Reg.  The second reason is that the stretch of amino acids precedes a
potential N-glycosylation site at position 126, thus indicating potential biological activity.
This pentadecapeptide, IGLHDPSHGTLPNGS, was synthesized and shown to
have activity in reversal of diabetes in animals (Rosenberg et al., 2000).  This smaller
version of INGAP should be easier to administer, have a longer half-life in vivo, and
cause fewer side effects.
The peptide nature of the 15-mer means it would still have to be injected into
patients and would be broken down rather quickly.  It would therefore be more desirable
to have a non-peptide compound with the same activity as the 15-mer.  We thought about
this and wanted to use our lab’s expertise in protein NMR to solve the structure of the 15-
mer and use that information to develop better therapeutics.  As will be shown in Chapter
3, the 15-mer has no stable structure in solution under the conditions we tested.  This led
us to believe that the 15-mer needed the surrounding protein to give it structure.
Therefore, we wanted to solve the INGAP structure and use that to come up with
synthetic targets for peptide mimetic drugs of the 15-mer.  We could not acquire INGAP,
so we used a homolog, INGAP-related protein (INGAPrP).
2.2 INGAPrP
Researchers in Japan wanted to identify the mouse version of INGAP.  What they
found was islet neogenesis associated protein-related protein (INGAPrP).  INGAPrP
mRNA was isolated from mouse and the predicted protein sequence was found to be 72%
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identical to INGAP (Figure 2.2) (Sasahara et al., 2000).  It was found by using the
primers for the INGAP gene to produce a PCR product from mouse duodenum cDNA.
The PCR product was sequenced and a mouse cDNA library was searched to determine if
the gene was already in a gene bank.  The gene was found in a mouse cDNA library and
had the accession number AA822059.
Figure 2.2 Sequence alignment of INGAP and INGAPrP.  The proteins are 72%
identical.  Identical residues are shown in pink.  Identical residues within the INGAP
pentadecapeptide region are underscored with blue stars.
INGAPrP was detected in various tissues throughout the mouse (Sasahara et al.,
2000).  Northern blot analysis confirmed INGAPrP’s presence in the pancreas and
duodenum, just like INGAP.  However, INGAPrP was also detected in the stomach and
skeletal muscle.  This was an unexpected result for the researchers because INGAP was
believed to be exclusively produced in regenerating pancreatic tissue.  Thus, the
researchers concluded their paper by essentially saying the gene was not likely to be
INGAP    MMLPMTLCRMSWMLLSCLMFLSWVEGEESQKKLPSSRITCPQGSVAYGSY
INGAPrP  MVSHKTLHSMSWMLLCCLMSLSWVQGEQSQKKLSSPRISCPQEAQAYGSY
INGAP    CYSLILIPQTWSNAELSCQMHFSGHLAFLLSTGEITFVSSLVKNSLTAYQ
INGAPrP  CYLLILEPQTWANAEIHCQKHFSGHLAFLLTYGEIIFVSSLVKNSLTTFP
INGAP    YIWIGLHDPSHGTLPNGSGWKWSSSNVLTFYNWERNPSIAADRGYCAVLS
INGAPrP  YIWIGLHDLSLGSLPNENGWKWSSSDPLTFYNWEIPPSMSAHHGYCAALS
            ***** * * ***
INGAP    QKSGFQKWRDFNCENELPYICKFK
INGAPrP  QASGYQKWRDYYCDPTFPYVCKFK
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useful in islet regeneration since it was detectable in normal pancreata and various other
mouse tissues (Sasahara et al., 2000).  However, it was later demonstrated that INGAP is
present in normal pancreases as well (Flores et al., 2003).  This leads us to believe that
INGAPrP may have regenerative capabilities after all.
Regardless of the activity of INGAPrP, structural studies of the protein would be
useful for gaining information about the INGAP pentadecapeptide’s structure.  INGAPrP
has a putative pentadecapeptide region very similar to INGAP’s pentadecapeptide (Figure
2.3).  Knowledge of this homologous region’s structure would be useful for making
mimics of the INGAP 15-mer.  It would also be interesting to know the structure of the
protein as a whole, which may lead to further insight into islet regenerative therapeutics.
2.3 The Reg Gene Family
INGAP belongs to the Reg gene family, which consists of members from several
species, including human, rat, mouse, hamster, and cow (Okamoto, 1999).  They have
been classified as either Reg I, Reg II, or Reg III proteins based on sequence homology.
They are all believed to be involved in some facet of islet regeneration.
Reg I proteins include: human Reg Ia, also known as pancreatic stone protein
(PSP), lithostathine, and pancreatic thread protein (PTP); human Reg Ib; rat Reg I; and
mouse Reg I.  The only Reg II protein is mouse Reg II, which has a unique sequence of
INGAP:     ….104IGLHDPSHGTLPNGS118….
INGAPrP: ….104IGLHDLSLGSLPNEN118….
Figure 2.3 Sequence identity between INGAP’s pentadecapeptide and INGAPrP’s
putative pentadecapeptide.  Identical residues are bold and underlined.
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seven amino acids at its N-terminus.  The Reg III proteins are: HIP, which is a gene
expressed in hepatocellular carcinoma, intestine, and pancreas; pancreatitis-associated
protein (PTP); rat Reg III, PAP I, PAP II, and PAP III; mouse Reg IIIa, b, g, and d;
hamster INGAP; and cow PTP.  INGAPrP was discovered after these designations, but
would belong in the mouse Reg III family.
A receptor for Reg I was identified from a rat islet cDNA library (Kobayashi et
al., 2000).  The gene for the receptor encodes a 919 amino acid protein.  The sequence
suggests that the protein is a type II transmembrane protein with a long extracellular
region, a transmembrane segment, and a short intracellular region at its amino-terminus.
Upon expression of the cDNA, it was found that rat Reg I bound to the receptor with
affinity in the low nanomolar range.  The Reg receptor has 97% identity to human
exostoses (EXT)-like gene 3 (EXTL3) and human EXT-related gene 1 (EXTR1),
signifying that the rat Reg receptor is a homolog of these human genes.
No reports have appeared in the literature regarding any studies of INGAP
binding or activating these receptors, and it is currently unknown which receptor INGAP
binds.  INGAP is believed to bind and activate a receptor since it is found in the acinar
cells and acts in a paracrine manner on the pancreatic ductal cells (Rafaeloff et al., 1997).
Knowing which receptor INGAP binds could provide a direct therapeutic target for islet
regeneration, and may allow researchers to manipulate the structure of potential drugs,
such as the INGAP pentadecapeptide, to increase their potency.
The only protein from the Reg family with a structure in the PDB is Lithostathine.
Its structure was determined to 1.3 angstroms via x-ray crystallography.  INGAP and
INGAPrP have 42% identity to Lithostathine, which can theoretically be relevant for
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homology modeling.  However, it is always better to have the structure determined
empirically.  Nonetheless, we created a homology model that will briefly be discussed in
Chapter 5.
2.4 Significance of Present Work
The present work provides a protocol for recombinant expression of INGAPrP in
E. coli.  Methods of purification, refolding, and 15N-labeling of INGAPrP are also
presented.  1H-15N HSQC and CD experiments indicate that our protocol provides a
folded protein, which will allow for structure determination.  Upon solving the three-
dimensional structure of INGAPrP it is believed that crucial knowledge regarding the
pentadecapeptide region will be gathered.  Structural insight can provide useful target
information for drug development.  In summary, this work is the first reported expression
and isolation of INGAPrP.
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CHAPTER 3
NMR STUDIES ON THE INGAP PENTADECAPEPTIDE
3.1 Purpose of the NMR Studies
Two-dimensional NMR was used to study the structure of the INGAP
pentadecapeptide.  Determining the fold of the 15-mer will provide insight into the active
conformation of the peptide.  With the knowledge of the pentadecapeptide’s
conformation, it is reasonable to believe that peptide mimetics could be designed.  This
would lead to non-peptide therapeutics that should have longer half-lives in vivo, better
oral bioavailability profiles, and may be more active.
3.2 Sample Preparation and Data Collection
The peptide was synthesized and purified by SynPep.  It was prepared with
acylation of the N-terminus and amidation at the C-terminus, yielding Ac-
IGLHDPSHGTLPNGS-NH2.  The molecular weight was verified to be 1543.0 daltons by
MALDI.  Purity was determined via HPLC.  The end result was a white powder, which
was received in our laboratory.
The 15-mer was determined to be soluble in a phosphate buffered solution.  A
phosphate solution is suitable for NMR studies because there are no 1H’s from the buffer
molecules to interfere with the spectrum.  However, since the peptide is in an aqueous
solution, a water suppression pulse sequence was needed to minimize the water signal,
thus maximizing the peptide signal.  WATERGATE was used to accomplish the water
suppression.
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All data were collected on a Bruker AVANCE DRX 500 NMR spectrometer.  The
experiments to perform for determining the structure of a small peptide are: one-
dimensional spectra, TOCSY, and ROESY (or NOESY).  The one-dimensional spectra
are useful to optimize the parameters of the sample, such as concentration, pH, and
temperature.  The first two-dimensional experiment to collect is the TOCSY, or total
correlation spectroscopy.  This experiment works by performing a “spin-lock” in the
pulse sequence that allows resonance to travel from the amide proton of a residue all the
way down that residue’s side-chain.  TOCSY is thus a through-bond experiment and
allows for assignment of which proton resonance frequencies belong to which proton in
the peptide.  ROESY is a through-space experiment and is critical for structure
determination because it determines which protons are close to each other in three-
dimensional space.  ROESY was chosen over NOESY because of the molecular weight
of the INGAP pentadecapeptide, which affects its correlation time, or tc.  ROESY’s pulse
sequence has a “mixing time” in which energy is transferred between protons within five
angstroms of each other in three-dimensional space.
3.3 Results
One-dimensional spectra were collected on a 5 mM solution in 10 mM phosphate
buffer.  The pH of the samples were varied from 5.5 to 7.0.  The spectra showed good
resolution of the proton signals, however some had less overlap than others.  From visual
inspection it was determined that the sample in pH 6.0 buffer gave the best signal
resolution.  The temperature was also varied and optimized.  It was determined that low
temperatures gave better resolution.  274 K was chosen as the optimal temperature.
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Figure 3.1 shows the amide region of the one-dimensional spectrum collected at pH 6.0
with a temperature of 274 K.  These are the conditions that the two-dimensional
experiments would be carried out at.
Figure 3.1 Amide region of  5 mM INGAP pentadecapeptide in 10 mM phosphate buffer
at pH 6.0 and 274 K.
TOCSY data was collected on the same sample.  A mixing time of 80 ms was
shown to give the best spectrum.  The spectrum used to assign the resonances is shown in
Figure 3.2.  The figure shows the amide region on the x-axis and the other protons (alpha,
beta, gamma, etc) on the y-axis.  The spectra on the left and top of the figure are from the
one-dimensional experiment for those regions.  Vertical lines illustrate where the energy
transfer has occurred in the two-dimensional experiment, each line correlating to a single
amino acid.  Table 3.1 shows the chemical shifts of the various protons for most residues.
Although not a complete assignment, this was enough information to proceed to the
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ROESY experiment.  It should also be pointed out that the proline residues do not have
any amide protons and therefore were not assigned.
Figure 3.2 TOCSY spectrum of INGAP pentadecapeptide.  The vertical lines indicate
energy transfer along an amino acid’s side-chain.
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The ROESY spectrum is shown in Figure 3.3.  This shows the full two-
dimensional spectrum of data collected with a mixing time of 250 ms, which was
determined to be the optimal mixing time.  The results were used for some sequential
assignment of amide and alpha protons (green circle, Figure 3.3) to trace the backbone of
the peptide, as well as verify the assignments from the TOCSY experiment.  However,
the small number of inter-residue crosspeaks does not bode well for structure
determination.
Figure 3.3 ROESY spectrum of INGAP pentadecapeptide.  Peaks within the green circle
were used for sequential assignment.
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3.4 Discussion
The one-dimensional experiments proved useful in determining the conditions to
use for the two-dimensional experiments.  The TOCSY data were encouraging and easy
to interpret.  Assignment of proton frequencies was achieved in a timely manner.
The ROESY experiment was a disappointment.  Although there were peaks
observed in the amide-alpha region, there were very few inter-residue crosspeaks.  The
amide-alpha region allows for sequential assignment, which is useful in assignment of
proton resonances.  The other regions are the more informative parts of the spectrum
because they show which protons are interacting in space.  These interactions are
absolutely crucial for structure determination because they allow for determination of
constraints when the data is entered into a computer modeling program.  Without a
significant number of these inter-residue interactions there is no way to determine a
structure.  Various mixing times were tried, as well as altering the pH, concentration of
the peptide, and temperatures without success.  NOESY data was collected as well, but
did not provide any more information than the ROESY.
The ROESY experiments essentially showed that the peptide had no stable
conformation in solution.  In hindsight, this was not very surprising.  The peptide is a
very small portion of the total INGAP protein, and since it is only a 15-mer it is unlikely
to show a specific fold.  The peptide also contains two glycines and two prolines.  These
residues are at two extremes in terms of peptide structure.  Glycine residues allow free
rotation around the residue because of the absence of any side-chain carbons.  Prolines
lock a peptide into a “kinked” conformation because of the side-chain folding back on
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itself at the amide nitrogen.  This severely restricts the conformations the peptide can
adopt.
In light of these results it is concluded that the INGAP protein likely holds the
pentadecapeptide into a stable, active conformation.  Homology modeling also points to
this conclusion (see Chapter 5).  It can also be reasoned that the peptide is active in vivo
even though it has no defined fold because it may bind to a receptor and subsequently
adopt a particular conformation which activates the receptor.  Activation of the receptor
would then trigger a signaling cascade giving the 15-mer its proliferative and
differentiating properties in vivo.  This hypothesis is also supported by the fact that the
full-length protein is 55-times more active than the 15-mer alone, meaning that the
protein may lock the active portion into an active conformation.
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CHAPTER 4
CLONING, EXPRESSION, AND PURIFICATION OF INGAPrP
4.1 Purpose of Recombinant Production of INGAPrP
INGAPrP production and isolation was desired to perform structural studies on
the protein.  The specific area of interest was the putative pentadecapeptide region, amino
acids 104-118.  This area is very similar to the INGAP 15-mer which is known to have
proliferative and differentiative function on pancreatic ductal cells.  Therefore, this
portion of INGAPrP is of particular interest from a structural standpoint.  Since the
INGAP pentadecapeptide was found to have no stable structure via two-dimensional
NMR experiments, we decided to study the entire INGAP-related protein (INGAPrP).
4.2 Construction of pINGAPrP Expression Vector
Standard molecular biology techniques were employed to produce the INGAPrP
expression vector.  The general strategy consisted of three parts.  The first phase was to
produce the INGAPrP gene via PCR.  The second step was to digest the PCR product and
the expression vector with the same restriction enzymes.  The final step in the scheme
was to ligate the gene and the plasmid to give the expression construct.  The resulting
construct was named pINGAPrP.
The INGAPrP gene was purchased from ResGen.  It was from a mouse cDNA
library and has the accession number AA822059 (Sasahara et al., 2000).  The signal
peptide of the protein was omitted from the PCR scheme because the INGAP signal
peptide was reported to be toxic to E. coli (Vinik et al., 1998).  We used the website
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http://www.stepc.gr/cgi-synaptic/sigfind to predict the signal peptide from the INGAPrP
protein.  The first 26 residues were classified as belonging to the signal sequence.  This is
the same section of the full-length INGAP protein that was determined to be the signal
peptide (Vinik et al., 1998).
For the expression system, we chose Novagen’s pET expression system (pET
System Manual, 1997).  This system uses a T7 RNA polymerase, which is inducible by
IPTG.  Once produced, the T7 RNA polymerase binds to the T7 promoter on the pET
expression construct, pINGAPrP, to produce large quantities of the pINGAPrP mRNA.
The mRNA is then translated into protein by the E. coli ribosome.
The pET vector chosen was pET 28b.  This vector is selectable by kanamycin,
which makes it easy to identify and use the resulting pINGAPrP construct.  The pET 28b
vector also has a hexahistidine-tag gene at the 5’-end of the multiple cloning site.  This
allowed for insertion of the INGAPrP gene into the multiple cloning site in such a way
that the resulting protein would have the 6X-His tag at its N-terminus.  The fusion tag
should allow for easier purification.
The PCR was performed with Vent DNA Polymerase (New England Biolabs) and
yielded a fragment with a 5’ NdeI site and a 3’ BamHI site.  Again, this omitted the
signal peptide.  Digestion of the PCR product and the pET 28b vector with the NdeI and
BamHI enzymes (New England Biolabs) were performed, and the products isolated by
agarose gel extraction.  This allowed for subsequent ligation of the two fragments with
T4 DNA ligase (New England Biolabs) in the presence of ATP.  After ligation, the
reactions were transformed into JM109 E. coli cells and plated on kanamycin
supplemented LB agar plates.  Colonies were picked, grown, and analyzed for correct
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insertion of the INGAPrP gene.  Ultimate verification of pINGAPrP was performed by
DNA sequencing from the T7 forward primer.  The DNA and protein sequences of
pINGAPrP are shown in Figure 4.1.
Figure 4.1  DNA and protein sequences for the pINGAPrP construct.  RBS is the
ribosome binding site.
4.3 Recombinant Expression of INGAPrP
Several E. coli cell lines were tried before an acceptable level of expression was
achieved from Rosetta (DE3) cells (Novagen).  These cells contain the pRARE plasmid
DNA       AAGGAGA TAT ACC ATG GGC AGC AGC CAT CAT CAT CAT CAT CAC AGC
pINGAPrP   *RBS*           M   G   S   S   H   H   H   H   H   H   S
DNA       AGC GGC CTG GTG CCG CGC GGC AGC CAT ATG GAA CAA TCC CAG AAA
pINGAPrP   S   G   L   V   P   R   G   S   H   M   E   Q   S   Q   K
DNA       AAA CTG TCT TCT CCA CGC ATC AGC TGT CCC CAA GAA GCC CAA GCT
pINGAPrP   K   L   S   S   P   R   I   S   C   P   Q   E   A   Q   A
DNA       TAT GGC TCC TAT TGC TAT TTA CTG ATT CTG GAA CCA CAG ACC TGG
pINGAPrP  Y    G   S   Y   C   Y   L   L   I   L   E   P   Q   T   W
DNA       GCT AAT GCA GAG ATC CAC TGC CAG AAG CAT TTC TCA GGA CAC CTG
pINGAPrP  A    N   A   E   I   H   C   Q   K   H   F   S   G   H   L
DNA       GCA TTT CTG CTC ACT TAT GGT GAA ATT ATC TTT GTG TCC TCT CTG 
pINGAPrP   A   F   L   L   T   Y   G   E   I   I   F   V   S   S   L
DNA       GTG AAA AAC AGT TTG ACC ACA TTC CCA TAC ATC TGG ATT GGA CTC 
pINGAPrP   V   K   N   S   L   T   T   F   P   Y   I   W   I   G   L
DNA       CAT GAT CTG TCA CTT GGG AGT TTG CCC AAT GAA AAT GGA TGG AAG
pINGAPrP   H   D   L   S   L   G   S   L   P   N   E   N   G   W   K
DNA       TGG AGC AGC TCT GAC CCT CTG ACC TTC TAT AAC TGG GAG ATA CCA
pINGAPrP   W   S   S   S   D   P   L   T   F   Y   N   W   E   I   P
DNA       CCC TCC ATG TCT GCA CAC CAC GGC TAC TGT GCA GCT TTG TCT CAG
pINGPrP    P   S   M   S   A   H   H   G   Y   C   A   A   L   S   Q
DNA       GCC TCA GGT TAT CAG AAG TGG AGA GAT TAT TAT TGT GAC ACA ATA
pINGAPrP   A   S   G   Y   Q   K   W   R   D   Y   Y   C   D   T   I
DNA       TTT CCC TAT GTC TGC AAA TTC AAG GGT TAG
pINGAPrP   F   P   Y   V   C   K   F   K   G *STOP*
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that codes for tRNAs rarely used by E. coli (Zhang et al., 1991).  Rosetta (DE3) cells
have been shown to increase eukaryotic gene expression levels in E. coli (Bukhtiyarova
et al., 2004; Diallo et al., 2005; Hedayati et al., 2005).  The pINGAPrP construct contains
nine rare codons (Table 4.1).  It is believed that these rare codons were causing
expression difficulties in the other cell lines available for T7 expression systems,
including DE3, DE3 (pLysS), and AD494.  Several other constructs were prepared and
tested in the various cell lines without pRARE, including a GST fusion protein and a pel-
B fusion protein, with no significant amount of expression.  A T5 expression system was
also tried (The QIAexpressionist, 2001), in which the same INGAPrP gene, without the
signal sequence, was cloned into a T5-compatible expression plasmid, pQE-31.
Expression was attempted in the T5 expression cell lines M15 (pREP4) and SG13009
(pREP4) with no success.
Table 4.1  Rare codons found in pINGAPrP.  The codons rarely used by E. coli are












Expressions were routinely carried out in one liter of LB broth supplemented with
kanamycin and chloramphenicol.  The kanamycin selected for the pINGAPrP vector,
while the chloramphenicol selected for the pRARE plasmid in the Rosetta (DE3) cells.
Expressions were always inoculated with a colony from a fresh transformation plate
ensuring the viability of the cells.
Optimal expression conditions were worked out for the pINGAPrP construct in
the Rosetta (DE3) cells.  An optical density, A600, of 0.55 was found to be the best for
induction.  A final concentration of 1 mM IPTG was determined to give the highest
expression levels of INGAPrP.  It was also discovered that a long expression period at a
low temperature was much better than the standard 3 to 4 hour expression at 37°C.
Therefore, cells were grown at 37°C until the desired density was reached, then they were
induced and placed at 27.7°C overnight.  The overnight expressions were allowed to go
for 15 to 17 hours.
In order to uniformly label the protein with 15N for heteronuclear NMR
experiments, we needed to use a different media than the LB.  LB contains many sources
of nitrogen and none of them are 15N-labeled.  Our first option was to use standard M-9
media.  M-9 consists of salts (Na2HPO4, KH2PO4, NaCl, MgSO4, and CaCl2), appropriate
antibiotics (kanamycin and chloramphenicol), glucose as a carbon source, and 15N-
labeled NH4Cl.
M-9 expression was attempted with the same conditions as the LB, but with very
poor yields (~0.3 mg/L cells).  It is likely that the cells could not grow as well in the
minimal media as they did in the LB.  A new method was needed.  It was found that there
are pre-made media that contain only 15N nitrogen sources.  These nitrogen sources are
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included in proteins, peptides, and vitamins, which will significantly aid the cellular
growth and subsequent recombinant protein production.
The media chosen was Spectra-9 media (Spectra Stable Isotopes).  The conditions
worked-out with the LB media worked well with the Spectra-9.  Yields were at least
seven-fold higher than with the M-9 media.  Although the yields from Spectra-9 were not
as high as for the LB, enough protein was produced for heteronuclear NMR experiments.
4.4 Initial Purification (IMAC) of INGAPrP
The purification and refolding scheme I planned to follow was the same that had
been used in our lab previously, to prepare the HTLV-1 protease.  The idea is simply to
purify the protein under denaturing conditions via an immobilized metal affinity
chromatography (IMAC) column.  This works by the interaction of Ni2+ and the
hexahistidine tag at the N-terminus of the recombinant protein.  After purification, the
protein is refolded by simple dialysis into the desired buffer for further experiments.
IMAC purification for INGAPrP removed a large amount of contaminating
proteins, but homogenous purification was never achieved.  Imidazole gradients, pH
gradients, and combinations of imidazole and pH were all attempted, but were
unsuccessful in complete purification of INGAPrP.
The procedure for producing partially purified INGAPrP from IMAC followed a
time-tested method for gathering protein from E. coli.  Briefly, the protein from the
Rosetta (DE3) cells was extracted from inclusion bodies with 6 M guanidine HCl and
buffer A (20 mM Tris, 500 mM NaCl, 5 mM imidazole at pH 7.9).  Guanidine HCl was
empirically determined to yield higher protein recovery than urea.  Once resuspended, the
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cells were lysed by sonication while on ice.  After two hours on ice, the lysate was
centrifuged, producing a pellet and a supernatant.  The pellet contained the cellular
debris, while the supernatant contained all the proteins, in guanidine.
The IMAC used was Ni-NTA (QIAGEN) and was prepared by flowing several
column volumes of 100 mM NiSO4 over the resin.  As mentioned, several purification
schemes were tried.  All of the purification procedures were carried out under denaturing
conditions in 6 M urea.  The SDS-PAGE analysis for two of the schemes are shown
below.  Figure 4.2 is representative of a gradual imidazole gradient used to wash away
impurities before elution.  Figure 4.3 shows the results from a pH gradient to wash away
contaminants, followed by an imidazole elution.  It is evident that neither of these
methods produce homogenous INGAPrP.
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Figure 4.2  Analysis of IMAC purification via imidazole gradient.  Lane 1: peptide
ladder (21.5 kD and 14.4 kD markers are labeled); Lanes 2-5: imidazole wash fractions
(5, 20, 50, 75 mM imidazole, respectively); Lanes 6-9: elution fractions (300 mM
imidazole).  The red circles high-light the impurities in the elution fractions.  The green
arrow shows INGAPrP at ~19.5 kD.
14.4 kD
21.5 kD
1 2 3 4 5 6 7 8 9
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Figure 4.3  Analysis of IMAC purification via pH gradient.  The left-most lane is the
peptide ladder (21.5 kD and 14.4 kD markers are labeled).  The other lanes are all elution
fractions following a pH gradient of 7.5, 6.3, 5.9, and 4.5.  The red circle high-lights the
impurities following the pH gradient.  The green arrow indicates INGAPrP at ~19.5 kD.
The method used to produce INGAPrP for further purification utilized an
imidazole gradient of 5 mM, 20 mM, and then elution with 1 M imidazole.  The gradient
was carried out under denaturing conditions in 6 M urea.  The SDS-PAGE analysis of




Figure 4.4  SDS-PAGE analysis of the elution fractions from IMAC following washes
with 5 mM and 20 mM imidazole.  INGAPrP is shown in the green box.  The impurities
are shown in the red box.
Since the protein was not purified to a high enough level, a second purification
step was needed.  It was initially planned to dialyze the elution fractions from IMAC into
a native buffer, then attempt size-exclusion chromatography or ion-exchange
chromatography.  This way the protein could be refolded, and then purified.  However,
this proved unsuccessful because the protein would not stay in solution upon dialysis.
Numerous dialysis methods were tried using literature methods (Clark, 1998).  The first
attempt was to dialyze directly from the 6 M urea in the elution fractions into a large
excess of native buffer.  Several conditions for the native buffers were altered such as pH,
salt and buffer composition, and temperature, with no change.  A step-wise urea gradient
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was attempted in which the protein was first dialyzed against a 5 M urea buffer, then a 4
M, and 3 M.  However, protein continually precipitated at a urea concentration lower
than ~3.5 M.  Several stabilizing additives were also tried, such as arginine, whose
structure mimics that of guanidine, and glycerol, which acts as a way to form small
micelles around the protein.
Ultimately, it was decided to attempt purification and folding on the same
column.  This would allow us to proceed with the partially pure, denatured, INGAPrP
from the IMAC step and move onto an FPLC system.  It was believed that we could
purify the protein and fold it all on a gel-permeation column (Gu et al., 2001; Shi et al.,
2003).  To try this, we concentrated the protein from IMAC down to a small volume for
FPLC work.
4.5 Secondary Purification (GPC) and Folding of INGAPrP
Gel permeation chromatography (GPC), also known as size-exclusion
chromatography, separates proteins based on their molecular weights.  The retention
times of the proteins are inversely related to their molecular weights.  Large proteins
come off the column first and small proteins elute later.  This is due to the small proteins
interacting with the beads longer than the large proteins.  The beads are very porous,
which allows for smaller proteins to pass into the beads whereas large proteins can not.
GPC was our method of choice to further purify the recombinantly expressed INGAPrP.
A Superdex 75 HR 10/30 column (Pharmacia) was used.  This column was in-line
on an Akta Explorer FPLC system.  The FPLC system is located in a cold room allowing
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for all purification steps to occur at 4°C.  This minimizes sample degradation and bacteria
or mold contamination in buffers.
To purify the protein, the column was first equilibrated with the buffer to be used
for purification, which was a 25 mM Tris, 150 mM NaCl buffer at pH 8.5 (at 4°C).  The
NaCl was added because the column specs call for at least 150 mM NaCl when purifying
protein.  The Tris buffer at a pH of 8.5 was chosen because this was the pH at which
INGAP was refolded (Vinik et al., 1998).
After equilibration, small protein samples, 250-500 mL, were injected onto the
column.  The Tris/NaCl buffer was used as the mobile phase.  Separation of the proteins
was evident by observing traces of A280 versus elution volume.  A typical trace from the
GPC can be seen in Figure 4.5.
Figure 4.5  A typical chromatogram from GPC purification of INGAPrP.  INGAPrP
elutes from 12.5 mL to 14.5 mL and is the largest peak.  The retention time corresponds
to a molecular weight of ~19.2 kD.  The inset shows a typical SDS-PAGE gel for the












The largest peak from the GPC purification was found to be INGAPrP.  A
standard curve for the Superdex 75 HR column was worked out using proteins of known
molecular weight by Dr. Charlie Oldham.  An equation was generated to determine the
molecular weight of an unknown protein based on its retention time on the column.  The
protein with a retention time of ~12.8 mL (retention time at maximal A280) was a protein
with an approximate molecular weight of 19.2 kD.  This was in the range of that expected
for INGAPrP.  The largest peak was run on an SDS-PAGE gel and found to match-up
with the most abundant protein from the IMAC column elution fraction (Figure 4.6).
This was identified as INGAPrP.
Figure 4.6  SDS-PAGE analysis of the largest peak from GPC (left lane) and elution
fraction from IMAC (right lane).  The peak from GPC matches the molecular weight of
the most abundant protein from the IMAC elutions.
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MALDI analysis showed that the largest peak from the GPC column had a
molecular weight of 19.404 kD (Figure 4.7).  This is 80 daltons more than the predicted
molecular weight.  This is likely the result of adducts, such as sodium, or the matrix,
being bound to the INGAPrP protein.
Figure 4.7  MALDI analysis of purified INGAPrP.  The parent ion (19.404 kD) gives the
molecular weight of INGAPrP.  The Z = 2+ peak is also present at 9.749 kD.
15N-labeled protein was purified in the same manner as for non-labeled samples.
Final yields after the GPC purification were 3.5 mg/L-cells from LB media, 0.3 mg/L-
cells from M-9 media, and 2.0 mg/L from Spectra-9 media.
To test the hypothesis that the protein from the GPC would be folded, we needed
to run a 1H-15N HSQC NMR experiment and CD experiments.  These are reported in the
following chapter.
























The pINGAPrP construct is capable of expressing mg quantities of INGAPrP in
Rosetta (DE3) E. coli cells.  This method will allow for either 15N-labeled or unlabeled
samples of protein to be produced.  Purification of INGAPrP by IMAC is insufficient to
yield highly pure protein.  Therefore a second purification step, GPC, was needed.  This




NMR, CD, AND OTHER STUDIES OF INGAPrP
5.1 NMR Experiments
The goal of this project was to determine the three-dimensional solution structure
of INGAPrP.  After isolation of the protein, the next step was to begin NMR
experimentation.  After GPC purification, the INGAPrP fractions were concentrated
down to a useful volume for NMR and D2O was added to a final concentration of 10%.
The one-dimensional experiment was conducted and concluded to be a success.
The purpose of the one-dimensional 1H NMR was to look for characteristics of a folded
protein.  There are two important regions for this.  The first is the amide region, or the 7-
11 ppm region.  A folded protein will have good resolution in this region with many
sharp peaks (Figure 5.1).  The high resolution indicates that the amide protons have their
own unique chemical environment.  An unfolded protein will have poor resolution in the
amide region, and will have very few, if any, sharp peaks (Figure 5.1).
The second important region in the 1H NMR spectrum is the area below zero ppm.
A folded protein will usually have a characteristic peak, or peaks, in this region (Figure
5.1).  In an unfolded protein, the peaks below zero ppm will be conspicuously absent
(Figure 5.1).  These peaks arise from a shielding effect experienced by a given proton.
The shielding is caused by aromatic side-chains interacting with other protons in three-
dimensional space, indicative of a folded structure.
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Figure 5.1  One-dimensional 1H NMR comparing “folded” and “unfolded” protein
samples.  The top spectrum illustrates an example of a folded protein.  The bottom
spectrum is for an unfolded sample.  The areas of interest are shown inside the colored
circles.  Note that neither of these examples are of INGAPrP, but rather are used to
illustrate “typical” one-dimensional NMR characteristics of proteins.
The INGAPrP sample, prepared from the IMAC and GPC chromatography,
displayed the characteristics of a folded protein in the one-dimensional 1H NMR.  The
spectrum can be seen in Figure 5.2.  With this initial promising result, the next step was




Figure 5.2  One-dimensional 1H NMR of purified INGAPrP.  The areas of interest are
shown inside the blue circles.  The protein appears to be folded.
The two-dimensional experiment of choice is the 1H-15N HSQC.  The HSQC is
chosen for several reasons.  First, it will give much better resolution of the amide region
than the 1H NMR because of its two dimensions.  Second, it is relatively easy to prepare a
sample for the experiment by labeling it with 15N.  This labeling is also much cheaper
than other labeling choices, such as 13C.  Also, the HSQC is a fairly quick experiment.
This experiment is the first step in multi-dimensional NMR experiments for structure
determination.
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The 1H-15N HSQC examines the protons connected to nitrogens.  These are
mostly from the protein’s backbone, with some coming from the various nitrogen-
containing side-chains.  A folded protein will give a broad dispersion of peaks in the
HSQC, whereas a non-folded protein will have poor resolution in the HSQC (Figure 5.3).
Figure 5.3  1H-15N HSQC of an unfolded protein.  This is an example illustrating the poor
resolution of an unfolded protein, and is not INGAPrP.
The INGAPrP sample was concentrated further and placed into a Shigemi tube for
the 1H-15N HSQC.  This was done to increase the effective concentration of the protein to
obtain an 1H-15N HSQC in a shorter time.  The resulting spectrum can be seen in Figure
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5.4.  It is apparent that the protein is folded because of the excellent dispersion of the
peaks.
Figure 5.4  1H-15N HSQC of purified INGAPrP.  The signal dispersion is indicative of a
folded state for INGAPrP.
This is a very promising result indicating that our method of purification also




structure of INGAPrP.  It should be noted that although the protein is folded, there is no
way to verify that this fold is the “correct”, or native, fold of INGAPrP.  The way to test
this would be to isolate INGAPrP directly from mouse pancreata and compare the
HSQCs and CD spectra.  Another option would be to test the recombinant INGAPrP for
activity in a functional assay.  If the protein is active then it would be considered to have
the correct fold.  An assay is underway with Dr. Alberto Hayek’s group at the University
of California at San Diego, however, results from the assay are unavailable at the time of
preparing this document.
5.2 CD
Circular dichroism (CD) is an experiment that is used to observe secondary
structure in proteins.  Circular dichroism is the result of a molecule absorbing left and
right circularly polarized light to a different extent.  The amide chromophore of the
peptide bond dominates the CD spectra below 250 nm.  Secondary structural elements in
a protein will cause characteristic CD spectra.  Examples of structural elements are
shown in Figure 5.5.
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Figure 5.5  CD spectra showing characteristics of alpha-helical, beta-sheet, and random
coil structures in proteins.
A CD was run on INGAPrP to complement the NMR conclusion that the purified
INGAPrP was folded.  The buffer and salt concentrations were reduced to 5 mM Tris and
30 mM NaCl to keep the voltage of the CD within an accurate range.  The pH was kept at
8.5.  The sample was diluted to a concentration of 25 mg/mL.
The CD results can be seen in Figure 5.6.  From visual inspection, it appeared that
there was some helical content in the spectrum.  This was verified by deconvolusion of
the CD data via a program called SELCON3 (Sreerama and Woody, 1993).  SELCON3
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works by taking CD data from proteins with known structures and then compares this
data set with the input CD data.  This program concluded that there were several helices
and at least one beta-sheet in INGAPrP from its CD.
Figure 5.6  CD spectra of 25 mg/mL INGAPrP under various conditions.  All TFE
measurements were done at 22.0°C.  1: 5 mM Tris, 30 mM NaCl, pH 8.5 at 22.0°C.  2:
5mM Tris, 30 mM NaCl, pH 8.5 at 90.0°C.  3: 20% TFE.  4: 30% TFE.  5: 40% TFE.  6:
50% TFE.  7: 60% TFE.
Further verification that there is helical content in INGAPrP was examined by
titrating in TFE to the protein sample.  TFE is known to induce helical content in

































crucial in helices.  A range of 20-60% TFE was used on INGAPrP.  With increasing TFE
concentration it is apparent that the helical content is increasing (Figure 5.6).
Finally, to further establish the fact that INGAPrP was folded, a simple
denaturation experiment was performed and a CD acquired.  INGAPrP was denatured by
heating it at 90.0°C for 15 minutes.  The denatured INGAPrP showed no signs of
secondary structure (Figure 5.6).
The CD data demonstrates the presence of secondary structure within INGAPrP.
It also indicates the presence of helical content within INGAPrP, which is useful
information for further structural studies of the protein.  Thus, the CD data complements
the NMR data indicating that INGAPrP is folded, and contains secondary structural
elements.
5.3 Degradation of INGAPrP
INGAPrP was found to degrade at 4°C after approximately seven days following
GPC purification.  This was observed by SDS-PAGE analysis and can be seen in Figure
5.7.  It was determined that the protein degraded to 16.1 kD by MALDI analysis (Figure
5.8).  This meant that the protein was “losing” roughly 30 amino acids from the full-
length protein expressed from the pINGAPrP construct.  The two possibilities for the
16.1 kD protein can be seen in Figure 5.9.
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Figure 5.7  SDS-PAGE analysis showing INGAPrP degradation after several days at
4°C.  The left lane shows INGAPrP following GPC.  The center lane shows INGAPrP
following IMAC purification.  The right lane shows degraded INGAPrP (red arrow).
Figure 5.8  MALDI analysis of degraded INGAPrP.  The parent peak is 16.113 kD and
the Z = 2+ peak is 8.052 kD.























Figure 5.9  Two possibilities for the 16.1 kD fragment of INGAPrP.  The residues that
would be removed following degradation are shown in red, with the corresponding
molecular weight of the remaining protein shown in the blue box (in kD).  The putative
pentadecapeptide region is shown in blue.
In order to determine which of the two possibilities in Figure 5.9 is correct, the
degraded sample was submitted for Edman degradation.  The sample was brought to Dr.
Jan Pohl at the Emory University Proteomics Facility.  Edman degradation determines
the N-terminal sequence of a protein.  The protein was subjected to eight rounds of
Edman sequencing and the results were SPRISCPQ as the N-terminus.  This means that
the protein is being degraded at the N-terminus of the full-length protein from the
pINGAPrP construct (top sequence in Figure 5.9).  Also, this result matches exactly with














The most logical explanation for the degradation is that a protease is cleaving the
INGAPrP.  Trace amounts of protease could theoretically remain with INGAPrP
following the GPC purification.  However, since cleavage is occurring between two
serine residues (Ser29 and Ser30), it is hard to say why the hypothetical protease would
not cleave the other Ser-Ser junctions within the remaining protein (Ser84-Ser85, Ser118-
Ser119, and Ser119-Ser120).  One possibility is that the other Ser-Ser sites are buried
within the protein and are not accessible to the protease.  It could also be reasoned that
the residues surrounding the other Ser-Ser sites do not accommodate the protease’s active
site, and thus can not be cleaved.  It should be pointed out that there is another Ser-Ser
site (Ser11-Ser12) within the N-terminus, which appears to be cleaved as evidenced by
SDS-PAGE (Figure 5.10).  This apparent specificity adds to the hypothesis that a
protease is responsible for the degradation at INGAPrP’s N-terminus.
Figure 5.10  SDS-PAGE showing a potential secondary degradation site within
INGAPrP’s N-terminus.  The left lane shows a sample that has degraded almost
completely to 16.1 kD.  The right lane shows a sample that has three bands; the top is
19.4 kD INGAPrP, the middle is an apparent fragment produced from cleavage between
Ser11-Ser12, and the lowest is the 16.1 kD INGAPrP.
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To test the hypothesis that INGAPrP is being degraded by a protease, a simple
experiment was designed.  A 19.4 kD INGAPrP sample was thawed from -20°C and
supplemented with a protease inhibitor cocktail, P8215, from Sigma-Aldrich.  The
cocktail contained AEBSF, E-64, Pepstatin A, and 1,10-Phenanthroline.  These
molecules inhibit serine proteases, cysteine proteases, aspartic acid proteases, and
metalloproteases, respectively.  After addition of the cocktail to the protein sample, the
sample was placed at 4°C for three weeks with aliquots being taken daily to monitor
degradation.  The positive control was a 19.4 kD INGAPrP sample thawed from -20°C
supplemented with no protease inhibitors.
The results were not expected.  The positive control showed no signs of
degradation after three weeks at 4°C (Figure 5.11).  The sample with the inhibitor
cocktail also showed no degradation following three weeks at 4°C (Figure 5.11).  Since
the positive control did not work, these test results can not verify the idea that the
degradation is being caused by a protease.
Figure 5.11  SDS-PAGE analysis of anti-degradation experiment.  The left lane shows a
16.1 kD INGAPrP sample.  The center lane shows a positive-control sample after three
weeks at 4°C.  The right lane shows a sample with the protease inhibitor cocktail after
three weeks at 4°C.
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It is unknown why the positive control did not undergo any degradation.  The
only difference between this full-length sample and other full-length samples that have
shown degradation is that this sample was frozen at -20°C for several weeks.  Samples
form the same batch of GPC purified protein underwent subsequent degradation, possibly
because they were never frozen, but rather kept at 4°C immediately following
purification.  This leads to the conclusion that whatever is causing the degradation is
somehow altered by freezing at -20°C, and thus rendered inactive.  This may be a
possible way to prevent degradation in the future.  However, before this method of
freezing INGAPrP following GPC purification is used, it should first be demonstrated
that there is no alteration to the protein fold following freezing.  This could be monitored
with NMR or CD.
In conclusion, regardless of how, or why, the protein is cleaved, the degradation
should not significantly affect the NMR structure determination.  Only eight residues
from the INGAPrP protein are lost, with the other 21 being from the pET 28b vector
(Figure 5.9).  Also, the putative INGAPrP pentadecapeptide region is still intact (Figure
5.9).  This is the region of ultimate interest for our purposes.
5.4 Homology Modeling
A homology model was constructed for reference purposes.  A modeling program
called molecular operating environment (MOE) was used.  A homology model was
constructed using the x-ray crystal structure of Lithostathine (Reg), PDB entry 1QDD, as
the template.  Lithostathine has 42% identity to INGAPrP and thus serves as a reasonable
template for INGAPrP modeling.
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The homology model can be seen in Figure 5.12.  It indicates some helical content
and some beta-sheet content, consistent with the CD data.  In my opinion, the interesting
part of the homology model is the area of the INGAPrP pentadecapeptide region.  This
region is shown in black in Figure 5.12.  It is apparent that the 15-mer is solvent exposed
and is in a turn conformation.  This could be a conformation that is able to bind and
activate its receptor.  This conformation will need to be verified experimentally by NMR,
or x-ray, structure determination before it will be of use for rational drug design.
Figure 5.12  Homology model of INGAPrP.  The model shows both helical and sheet
contents.  The pentadecapeptide region is shown in black.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK
This is the first report of the expression, purification, and refolding of INGAPrP.
Also reported is the initial step in NMR structure determination of the protein, the 1H-15N
HSQC.  Circular dichroism experiments indicate that INGAPrP contains helical elements
in its secondary structure.  Although this is a start for our ultimate goals with this project,
much is left to be done.
There are two logical steps to be taken following the work presented here.  The
first step is to fully determine the three-dimensional NMR solution structure of
INGAPrP.  The 1H-15N HSQC is proof that the protocol for isolation of INGAPrP yields a
folded protein for the conditions tested, and therefore can be used for structure
determination.  The second main objective should be to investigate the activity of
INGAPrP.  A collaboration with Dr. Alberto Hayek at the University of California at San
Diego is currently underway to test the activity of INGAPrP in proliferating and/or
differentiating human ductal cells and/or human fetal pancreatic cells in vitro.  This
should provide an answer as to the desired, and anticipated activity of INGAPrP.
There are several other projects that can be imagined pertaining to the work
described here.  A mutant of INGAPrP was prepared by myself in which the putative
INGAPrP pentadecapeptide region was successfully mutated to the INGAP
pentadecapeptide (i.e. IGLHDLSLGSLPNEN to IGLHDPSHGTLPNGS).  This would be
an interesting molecule to look at structurally, because it should alleviate the problems
we had with looking at the 15-mer in solution, since the INGAPrP protein would likely
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act as a scaffold to hold the 15-mer in place.  It would also be interesting to test the
activity of this mutant.
Assuming that INGAPrP has activity similar to INGAP, it would be interesting to
evaluate which part of the protein is the active portion.  Studies should also be done with
the putative INGAPrP pentadecapeptide in vitro, as well as the putative Reg
pentadecapeptide, to compare the activity of these peptides with that of the INGAP 15-
mer.  Further studies along the same vein would be to perform an alanine-scan on the
various peptides.  For example, one could mutate each of the 15 residues in the INGAP
pentadecapeptide to an alanine to produce 15 separate peptides.  The activity of these
peptides could indicate which residues are critical for activity and which ones could be
altered.  A subsequent study could then be envisioned in which a library of compounds is
made by using various amino acids in the place of non-critical residues within the 15-
mer.
The last set of experiments that are of interest would involve identification of a
receptor for INGAPrP, INGAP, and the INGAP pentadecapeptide.  There are some
candidate receptors from the literature, including the rat Reg receptor and its human
homologs.  Various libraries of receptors could also be screened.  Once a receptor is
identified, it would be useful to investigate the signaling cascade that these differentiation
factors induce.  This could lead to additional therapeutic targets.  A receptor would also
be useful for SAR by NMR studies in which one could determine precisely which
residues of the INGAPrP protein, or the INGAP pentadecapeptide, bind to the receptor
(Shuker et al., 1996).  This would provide key information for drug development of
smaller molecules.
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In summary, a solid foundation has been laid for the INGAPrP project, but much
is left to be explored and discovered.  It is my belief that once these additional projects





INGAPrP expression plasmid construct
INGAPrP cDNA (accession number AA822059) was obtained from ResGen.  The
INGAPrP gene without the putative signal peptide was produced via PCR with the
pr imers  5’ -CGTAGTCATATGGAACAATCCCAGAAA-3’  and  5’ -
CGTAGTGGATCCCTAACCCTTGAATTT-3’.  The underlined bases correspond to
NdeI and BamHI restriction enzyme sites, respectively.  The PCR was carried out over 30
cycles of 95°C for 1 minute, 58°C for 1 minute, and 72°C for 1 minute using Vent DNA
polymerase (New England Biolabs).  The expression plasmid pET 28b (Novagen) was
used as the vector.  Double enzymatic digests with NdeI and BamHI (New England
Biolabs) were performed on both the PCR product and the pET 28b plasmid.  A
subsequent ligation reaction was performed with T4 DNA Ligase (New England Biolabs)
in the presence of ATP to yield the desired construct, pINGAPrP.  The ligation reaction
was transformed into JM109 cells and grown on LB agar supplemented with 30 µg/mL
kanamycin.  A colony was picked from the agar plate and grown in LB media
supplemented with kanamycin.  A cell stock was made by adding 500 µL 7% DMSO to
500 µL cells and frozen at -80°C.  DNA from the cells was isolated by Qiagen
preparation.  DNA sequencing, carried out at the Georgia Tech Biology Core Lab, using
the T7 forward primer, verified the accuracy of pINGAPrP.
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Expression of INGAPrP
pINGAPrP was transformed into Rosetta (DE3) cells (Novagen) and plated on LB-
kanamycin/chloramphenicol (30 µg/ml and 34 µg/ml respectively).  Colonies were
picked and grown in flasks containing one-liter LB or Spectra-9 media (Spectra Stable
Isotopes) supplemented with kanamycin and chloramphenicol.  The growths were carried
out at 37°C until an O.D.600 of 0.5-0.6 was reached, at which time IPTG was added to a
final concentration of 1 mM.  The cells were left in the presence of IPTG at 27.7°C for
15-20 hours to produce INGAPrP.  Cells were pelleted at 5K RPM and resuspended in a
denaturing buffer composed of buffer A (20 mM Tris, 500 mM NaCl, 5 mM imidazole at
pH 7.9) with 6M guanidine HCl.  The resuspended cells were lysed by sonication and left
on ice for 3 hours to allow extraction of the protein in inclusion bodies.  The mixture was
spun at 14K RPM to separate the cellular debris from the protein solution.  The
supernatant containing the INGAPrP protein was saved for purification.
Initial Purification of INGAPrP by IMAC Chromatography
A 5 mL Ni-NTA (QIAGEN) resin bed was used for the IMAC purification step.  All
steps were carried out at 22°C.  The column was equilibrated with 4 column volumes
(CV) 0.5 M NaOH, 5 CV dI H2O, 4 CV 100 mM NiSO4, 3 CV buffer C (buffer A with 20
mM imidazole and 6 M urea) and then the supernatant was flowed over the resin.  The
protein was purified with 8 CV buffer B (buffer A with 6 M urea), 7 CV buffer C, and
eluted with 6 CV buffer D (buffer B with 1 M imidazole).  The elution fraction was
concentrated down to a final volume of 5 mL for secondary purification.  Protein was
concentrated with Amacon concentrators with 3.5 kD MWCO.
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Secondary Purification and Folding of INGAPrP by GPC Chromatography
A Superdex 75 HR column was used for GPC purification in-line on an AKTA Explorer
FPLC system at 4°C.  The column was equilibrated with 2 CV 25 mM Tris, 150 mM
NaCl at pH 8.5.  500 µL protein from the IMAC column was injected onto the GPC
column and the 25 mM Tris, 150 mM NaCl buffer was used as the mobile phase.  The
largest peak in the chromatogram, corresponding to a ~19.2 kD protein was saved at 4°C
for NMR studies.  Multiple injections of 500 µL protein were made and the INGAPrP
fractions were pooled.  MALDI analysis of the resultant protein was done at Georgia
Tech by Dr. Cameron Sullards.
NMR Spectroscopy
A 0.5 mM protein sample was prepared by concentrating the GPC purified protein to a
final volume of 300 µL after the pH of the solution was adjusted to 6.9 and D2O was
added to a final concentration of 10%.  The protein solution was placed into a Shigemi
tube and NMR data was collected on a Bruker AVANCE DRX 500 at 22°C.  The water
signal was suppressed with WATERGATE.  HSQC data was collected with 320 scans.
CD
Far-UV (202-250 nm) CD spectra were collected on a JASCO J-810 CD
spectropolarimeter with a quartz cell having 1 cm path length.  The concentration of
INGAPrP was kept constant at 25 µg/mL for all CD measurements.  An initial spectrum
was collected in 5 mM Tris, 30 mM NaCl at pH 8.5 at 22.0°C.  This sample was then
heated to 90.0°C by a Peltier temperature control and another spectrum collected after the
69
protein was allowed to denature for 15 minutes.  Finally, CD data was collected in the
presence of 20%, 30%, 40%, 50%, and 60% 2,2,2-Trifluoroethanol (TFE) at 22.0°C.
Each spectrum was compiled by averaging four scans and all spectra were baseline-
corrected by subtracting out the buffer spectrum.
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